Abstract 172P
Background
Several inflammation-based markers were found to have a prognostic value in malignancies. Recent studies have reported that the preoperative neutrophil-to-lymphocyte ratio (NLR) is useful for prognostication in a variety of oncologic patients. We analyzed the NLR in determining Pancreatic neuroendocrine neoplasm (PanNEN) clinical outcomes after surgery.
Methods
We evaluated 132 consecutive cases of PanNEN who underwent surgery in Tohoku University Hospital between May 2001 and December 2018. Eight patients with synchronous hepatic metastasis, two patients with NEC, one patient with an active infection at blood sampling, and one patient with R2 noncurative resection were excluded from the study. 120 patients divided into two groups according to the values of NLR based on the receiver operator characteristic (ROC) curve. Differences of the characteristics between the two NLR groups (<3.84 vs. ≥3.84) were investigated with the chi-squared test and the Wilcoxon rank-sum test. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated by univariate or multivariate analyses using Cox’s proportional hazards model.
Results
The median age was 60 years old (range 12-88). In the WHO2017 histological grade, NET G1, G2, and G3 included 74, 44, and 2 cases, respectively. The median follow-up period was 52.9 months (range, 1-182). The NLR values distributed between 0.44 and 5.32 (average 1.92 ± 0.88). Five- and ten‐year RFS was 90.4% and 80.1%, respectively. Ten (8.3%) cases of relapse were observed. The site of recurrence was liver in nine patients and lymph node metastasis in one. NLR showed a significant correlation with RFS (median RFS time, 44.6 months (NLR ≥ 3.84) and not reached (NLR <3.84), p < 0.001). The multivariate analysis identified ki67 (≥3.4 HR 8.9; 95% CI 2.14 to 60.3; P = 0.002), and preoperative NLR (≥3.84 HR 7.7; 95% CI 1.63 to 30.1; P = 0.013) were an independent predictor of recurrence.
Conclusions
NLR could be a useful prognostic marker of the recurrence estimation after surgery and a handy objective screening tool for the host immune response in patients with PanNEN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract